(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
Live Chart Being Loaded With Signals
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding...
Stats | |
---|---|
Šios dienos apimtis | 550 055 |
Vidutinė apimtis | 776 085 |
Rinkos kapitalizacija | 315.45M |
EPS | CHF0 ( 2024-05-17 ) |
Kita pelno data | ( CHF-0.150 ) 2024-06-21 |
Last Dividend | CHF0 ( N/A ) |
Next Dividend | CHF0 ( N/A ) |
P/E | -4.54 |
ATR14 | CHF0.0130 (0.41%) |
Tūris Koreliacija
AC Immune SA Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ADPT | 0.896 |
ASTS | 0.889 |
WKHS | 0.888 |
NEOG | 0.881 |
SCPH | 0.881 |
SOPA | 0.881 |
AEHR | 0.88 |
OM | 0.88 |
ALTM | 0.877 |
BCDA | 0.876 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
KRUS | -0.862 |
MASI | -0.835 |
SFBC | -0.828 |
ADTH | -0.827 |
KINS | -0.822 |
INBKZ | -0.819 |
EDAP | -0.818 |
EDUC | -0.815 |
LPCN | -0.812 |
TAYD | -0.81 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
AC Immune SA Koreliacija - Valiuta/Žaliavos
AC Immune SA Finansinės ataskaitos
Annual | 2023 |
Pajamos: | CHF14.80M |
Bruto pelnas: | CHF-39.81M (-268.93 %) |
EPS: | CHF-0.640 |
FY | 2023 |
Pajamos: | CHF14.80M |
Bruto pelnas: | CHF-39.81M (-268.93 %) |
EPS: | CHF-0.640 |
FY | 2022 |
Pajamos: | CHF3.94M |
Bruto pelnas: | CHF-56.40M (-1 433.32 %) |
EPS: | CHF-0.850 |
FY | 2021 |
Pajamos: | CHF0.00 |
Bruto pelnas: | CHF0.00 (0.00 %) |
EPS: | CHF-0.970 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.